In 'Conservative' Estimate, Investment Firm Predicts PacBio Will Ship 46 Instruments in 2011
April 19, 2011
In 'Conservative' Estimate, Investment Firm Predicts PacBio Will Ship 46 Instruments in 2011
William Blair initiated coverage of PacBio this week, but predicted slightly lower instrument sales than consensus estimates due to "uncertainty about the adoption trajectory beyond early users."
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- PacBio Demos Improved Chemistry with E. coli Outbreak Sequencing; Plans Q4 Upgrade for RS
July 12, 2011 / In Sequence - PacBio's XL Chemistry Increases Read Lengths and Throughput; CSHL Tests the Tech on Rice Genome
November 13, 2012 / In Sequence - PacBio's Base-Modification Analysis IDs Epigenetic Markers in Microbes, Pathogens
July 3, 2012 / In Sequence - Booking 6 Systems in Q4, PacBio Begins C2 Upgrades, Will Focus on Niche Applications
February 14, 2012 / In Sequence - Korean Service Provider to Offer NGS on PacBio
February 14, 2012 / In Sequence